Scarica l'app Stockscreener
4.08
5.12%
-0.22
Pre-mercato:
4.08
Precedente Chiudi:
$4.30
Aprire:
$4.29
Volume 24 ore:
2.55M
Relative Volume:
0.66
Capitalizzazione di mercato:
$663.73M
Reddito:
$400.57M
Utile/perdita netta:
$9.21M
Rapporto P/E:
102.00
EPS:
0.04
Flusso di cassa netto:
$146.36M
1 W Prestazione:
+21.07%
1M Prestazione:
+17.24%
6M Prestazione:
+472.23%
1 anno Prestazione:
-9.93%
Intervallo 1D:
$4.05
$4.29
Intervallo di 1 settimana:
$4.05
$5.78
Portata 52W:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Nome
Ironwood Pharmaceuticals Inc
Settore
Telefono
617-621-7722
Indirizzo
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Confronta IRWD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
4.08 | 699.52M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
125.67 | 57.00B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.90 | 49.88B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.05 | 45.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 36.84B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
52.88 | 16.33B | 0 | -5.87M | -767.30K | -0.45 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | Downgrade | Jefferies | Buy → Hold |
| 2025-04-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-08 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Wells Fargo | Overweight |
| 2023-11-09 | Iniziato | Jefferies | Buy |
| 2023-09-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-02 | Iniziato | CapitalOne | Overweight |
| 2022-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Iniziato | Northland Capital | Outperform |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Iniziato | H.C. Wainwright | Sell |
| 2018-05-09 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Downgrade | Mizuho | Buy → Neutral |
| 2017-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Iniziato | Wells Fargo | Outperform |
| 2017-04-07 | Reiterato | Mizuho | Buy |
| 2017-02-22 | Reiterato | Barclays | Equal Weight |
| 2016-11-04 | Reiterato | Mizuho | Buy |
| 2016-10-24 | Reiterato | Wedbush | Neutral |
| 2016-10-10 | Reiterato | Mizuho | Buy |
| 2016-09-27 | Reiterato | WallachBeth | Hold |
Mostra tutto
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating - MarketBeat
5 Small Drug Stocks to Buy as Industry Recovery Picks Up - Yahoo Finance
Ironwood stock rises 27% on upbeat revenue guidance for 2026 - MSN
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Craig Hallum - MarketBeat
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 32% Share Price Rise - 富途牛牛
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry - simplywall.st
Citizens Upgrades Ironwood Pharmaceuticals (IRWD) - Nasdaq
Wells Fargo Raises Target Price for IRWD to $5.00 Maintaining Eq - GuruFocus
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 - Finviz
Wells Fargo & Company Forecasts Strong Price Appreciation for Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock - MarketBeat
Ironwood Pharmaceuticals Inc. (IRWD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
The Five-year Loss for Ironwood Pharmaceuticals (NASDAQ:IRWD) Shareholders Likely Driven by Its Shrinking Earnings - 富途牛牛
Ironwood Pharmaceuticals (IRWD) Upgraded to Market Outperform by Citizens | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED) - Benzinga
Craig-Hallum Boosts Ironwood (IRWD) Rating with Optimistic Outlo - GuruFocus
Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift - TechStock²
Ironwood Pharmaceuticals stock price target raised to $5 by Wells Fargo - Investing.com Canada
Citizens upgrades Ironwood Pharmaceuticals stock rating on LINZESS strength By Investing.com - Investing.com Canada
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Nasdaq Futures Pipeline Depth - Kalkine Media
Promising Pharmaceutical Stocks To ConsiderJanuary 2nd - MarketBeat
Ironwood Pharmaceuticals Surges on Linzess Sales Boost - StocksToTrade
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - MSN
Ironwood Pharmaceuticals’ Stock Surges as Higher Linzess Sales Drive Market Excitement - timothysykes.com
Ironwood Pharma leaps on 2025/2026 guidance - The Pharma Letter
Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M - Yahoo Finance
Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Ironwood Pharmaceuticals: Market Response to Legal Settlement - StocksToTrade
Ironwood Pharma (IRWD) Surges on Strong FY26 Guidance and Pipeli - GuruFocus
Stock soars at Boston biotech after it cuts price of IBS drug - The Business Journals
Ironwood Pharmaceuticals Stock (IRWD) Opinions on 2026 Financial Guidance - Quiver Quantitative
Ironwood Pharmaceuticals Stock Soars as Drug-Price Cut Boosts Prospects for 2026 - Barron's
Ironwood Pharmaceuticals stock soars on strong 2026 guidance By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals stock soars on strong 2026 guidance - Investing.com
Stock Traders Buy High Volume of Ironwood Pharmaceuticals Call Options (NASDAQ:IRWD) - MarketBeat
Ironwood Reaffirms FY2025 Revenue Outlook, Sees Growth In FY2026; Stock Surges - RTTNews
Ironwood Pharmaceuticals (NASDAQ:IRWD) Hits New 12-Month HighHere's Why - MarketBeat
Ironwood Pharmaceuticals, Baidu, Vertiv Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
Why did Ironwood Pharmaceuticals stock skyrocket today? - MSN
Ironwood Pharma Stock Rallies On Strong 2026 OutlookIronwood Pharmaceuticals (NASDAQ:IRWD) - Benzinga
Why Did Ironwood Pharmaceuticals Stock Skyrocket Today? - Stocktwits
Ironwood’s Recent Move: A Catalyst for Change? - timothysykes.com
Why Is IRWD Stock Soaring Over 30% Premarket? 2026 Revenue Outlook Beats Estimates - Tokenist
Ironwood (IRWD) Focuses on Financial Growth and Drug Development - GuruFocus
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Year 2025 and Provides Earnings Guidance for Year 2026 - MarketScreener
Ironwood Pharmaceuticals (IRWD) Projects Strong Revenue Growth f - GuruFocus
Ironwood beats on 2026 outlook thanks to AbbVie-partnered Linzess - MSN
Ironwood Pharma Provides FY26 Outlook, Maintains Full Year Outlook - Nasdaq
Ironwood forecasts 2026 LINZESS sales to exceed $1.1 billion - Investing.com
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance - TradingView — Track All Markets
Ironwood surges after forecasting Linzess' reentry into blockbuster territory - FirstWord Pharma
Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.03%
2.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):